타이틀

Y-biologics Inc., a South Korean biopharmaceutical firm, and U.S.-based biotechnology venture Genosco Inc. have recently signed a contract for cancer drugs research and development

South Korean pharmaceutical giant Yuhan announced Monday that it had licensed out its new clinical-stage lung cancer drug to Janssen Biotech in a deal potentially valued at up to $1.25 billion